ArticlePharmaceuticals (Basel, Switzerland)2021
Potent Antiviral Activity against HSV-1 and SARS-CoV-2 by Antimicrobial Peptoids.
Article in Pharmaceuticals (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 54 citations in OpenAlex.
- Recent progress in the structure-activity relationship of antibacterial peptoids.RSC advances · 2026Review
- In Vivo Activity of Antimicrobial Peptoid Oligomers against HSV-1 in a Mouse Model of Herpes Labialis.ACS infectious diseases · 2026Article
- Antimicrobial peptoids pass rapidly through bacterial membranes and flocculate ribosomes and DNA: A single-cell fluorescence study.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Noncanonical Folding of Peptoid Oligomers: Formation of a Closed Conformation in Nonpolar Solvent.Organic letters · 2026Article
- Antiparasitic effect of peptoids againstMicrobiology (Reading, England) · 2025Article
- Membrane-Targeting Antivirals.International journal of molecular sciences · 2025Review
- Structural Optimization of Antifungal Peptoids targetingACS medicinal chemistry letters · 2025Article
- Harnessing Non-Antibiotic Strategies to Counter Multidrug-Resistant Clinical Pathogens with Special Reference to Antimicrobial Peptides and Their Coatings.Antibiotics (Basel, Switzerland) · 2025Review
- Cryogenic Electron Microscopy of Rift Valley Fever Virus.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Identification of cannabinoid-sensitive and -resistant oral bacteria.Frontiers in microbiology · 2025Article
- Review
- From a focal skin issue to a systemic disease: the multifaceted nature of cold sores, novel findings.Virusdisease · 2024Article
- Peptide-mimetic treatment of Pseudomonas aeruginosa in a mouse model of respiratory infection.Communications biology · 2024Article
- Anti-Neuroinflammatory Effects of a Macrocyclic Peptide-Peptoid Hybrid in Lipopolysaccharide-Stimulated BV2 Microglial Cells.International journal of molecular sciences · 2024Article
- The activity of antimicrobial peptoids against multidrug-resistant ocular pathogens.Contact lens & anterior eye : the journal of the British Contact Lens Association · 2024Article
- Antiviral Effect of Antimicrobial Peptoid TM9 and Murine Model of Respiratory Coronavirus Infection.Pharmaceutics · 2024Article
- Antiviral effect of peptoids on hepatitis B virus infection in cell culture.Antiviral research · 2024Article
- Supramolecular Peptoid Structure Strengthens Complexation with Polyacrylic Acid Microgels.Biomacromolecules · 2024Article
- A novel film spray containing curcumin inhibits SARS-CoV-2 and influenza virus infection and enhances mucosal immunity.Virology journal · 2024Article
- Enhancement of innate immunity in gingival epithelial cells by vitamin D and HDAC inhibitors.Frontiers in oral health · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 6 institutions in 2 countries.
Funding
Abstract
Viral infections, such as those caused by Herpes Simplex Virus-1 (HSV-1) and SARS-CoV-2, affect millions of people each year. However, there are few antiviral drugs that can effectively treat these infections. The standard approach in the development of antiviral drugs involves the identification of a unique viral target, followed by the design of an agent that addresses that target. Antimicrobial peptides (AMPs) represent a novel source of potential antiviral drugs. AMPs have been shown to inactivate numerous different enveloped viruses through the disruption of their viral envelopes. However, the clinical development of AMPs as antimicrobial therapeutics has been hampered by a number of factors, especially their enzymatically labile structure as peptides. We have examined the antiviral potential of peptoid mimics of AMPs (sequence-specific
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.